# Evaluation of Clinical Outcomes, Tolerability, and Costs of Avelumab Maintenance and Pembrolizumab Second-Line Therapy in Advanced Urothelial Cancer.

> **NCT07207928** · — · COMPLETED · sponsor: **Azienda Ospedaliera Universitaria Integrata Verona** · enrollment: 35 (actual)

## Conditions studied

- Urothelial Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07207928
- **Lead sponsor:** Azienda Ospedaliera Universitaria Integrata Verona
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2024-09-16
- **Primary completion:** 2025-02-21
- **Final completion:** 2025-12-22
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2026-01-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07207928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07207928, "Evaluation of Clinical Outcomes, Tolerability, and Costs of Avelumab Maintenance and Pembrolizumab Second-Line Therapy in Advanced Urothelial Cancer.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07207928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*